World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
78
Citations
24346
World Ranking
17981
National Ranking
8963

Overview

Douglas S. Goodin is affiliated with the University of California, San Francisco in the United States. Their research primarily centers on the field of medicine, with a focus on pathology and forensic medicine, neurology, immunology, rheumatology, and radiology, nuclear medicine, and imaging.

The scientist's work addresses major topics related to multiple sclerosis research studies, T-cell and retrovirus studies, neuroinflammation and neurodegeneration mechanisms, systemic lupus erythematosus research, advanced neuroimaging techniques and applications, long-term effects of COVID-19, and peripheral neuropathies and disorders.

Douglas S. Goodin has contributed to several peer-reviewed research papers. Notable recent publications include:

  • Synaptic injury in the inner plexiform layer of the retina is associated with progression in multiple sclerosis, 2024, Cell Reports Medicine
  • Spinal Cord Atrophy Predicts Progressive Disease in Relapsing Multiple Sclerosis, 2021, Annals of Neurology
  • The nature of genetic and environmental susceptibility to multiple sclerosis, 2021, PLoS ONE
  • Neurite Orientation Dispersion and Density Imaging for Assessing Acute Inflammation and Lesion Evolution in MS, 2020, American Journal of Neuroradiology
  • An electronic, unsupervised patient-reported Expanded Disability Status Scale for multiple sclerosis, 2020, Multiple Sclerosis Journal

Douglas S. Goodin frequently collaborates with other researchers in the field. Common coauthors include Riley Bove, Bruce Cree, Stephen L. Hauser, Refujia Gomez, and Jeffrey M. Gelfand.

The scientist's publications are often found in prominent venues related to neurology and medicine, including Annals of Neurology, PLoS ONE, American Journal of Neuroradiology, Cell Reports Medicine, and Journal of Neurology Neurosurgery & Psychiatry.

Best Publications

  • Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines.

    D. S. Goodin;Elliot Frohman;G. P. Garmany;J. Halper

  • Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.

    Peter A. Calabresi;Ernst Wilhelm Radue;Douglas Goodin;Douglas Jeffery

  • Age-related variations in evoked potentials to auditory stimuli in normal human subjects

    Douglas S Goodin;Kenneth C Squires;Beverley H Henderson;Arnold Starr

  • Assessment: Transcranial Doppler ultrasonography: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

    M. A. Sloan;M. A. Sloan;Andrei Alexandrov;C. H. Tegeler;M. P. Spencer

  • Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial.

    Hillel Panitch;D. S. Goodin;G. Francis;P. Chang

  • Long latency event-related components of the auditory evoked potential in dementia

    Douglas S. Goodin;Kenneth C. Squires;Arnold Starr

  • INCIDENTAL MRI ANOMALIES SUGGESTIVE OF MULTIPLE SCLEROSIS: THE RADIOLOGICALLY ISOLATED SYNDROME

    Darin Okuda;E. M. Mowry;A. Beheshtian;E. Waubant

  • Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis

    Sergio E. Baranzini;Joanne Wang;Rachel A. Gibson;Nicholas Galwey

  • 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

    Paul O'Connor;Massimo Filippi;Barry Arnason;Giancarlo Comi

  • Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trial

    Jerry S. Wolinsky;Ponnada A. Narayana;Paul O'Connor;Patricia K. Coyle

  • Silent progression in disease activity-free relapsing multiple sclerosis.

    Bruce A C Cree;Jill A Hollenbach;Riley Bove

  • Assessment: Prevention of post-lumbar puncture headaches: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

    Randolph W. Evans;Randolph W. Evans;Carmel Armon;Elliot M. Frohman;Douglas S. Goodin

  • Mapping Multiple Sclerosis Susceptibility to the HLA-DR Locus in African Americans

    Jorge R. Oksenberg;Lisa F. Barcellos;Bruce A.C. Cree;Sergio E. Baranzini

  • HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course

    L.F. Barcellos;J.R. Oksenberg;A.B. Begovich;E.R. Martin

  • Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis

    B. A.C. Cree;O. Khan;D. Bourdette;D. S. Goodin

  • Clinical utility of surface EMG Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

    S.L. Pullman;D.S. Goodin;A.I. Marquinez;S. Tabbal

  • Survival in MS A randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial

    D.S. Goodin;A.T. Reder;G.C. Ebers;G. Cutter

  • Mortality in patients with multiple sclerosis

    Antonio Scalfari;Volker Knappertz;Gary Cutter;Douglas S. Goodin

  • Electrophysiological differences between subtypes of dementia.

    Douglas S. Goodin;Michael J. Aminoff

  • IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event.

    Douglas S. Goodin

Frequent Co-Authors

Michael J. Aminoff
Michael J. Aminoff University of California, San Francisco
Anthony T. Reder
Anthony T. Reder University of Chicago
Bruce A. C. Cree
Bruce A. C. Cree University of California, San Francisco
Stephen L. Hauser
Stephen L. Hauser University of California, San Francisco
George C. Ebers
George C. Ebers University of Oxford
Barry G. W. Arnason
Barry G. W. Arnason University of Chicago
Ludwig Kappos
Ludwig Kappos University Hospital of Basel
Gary Cutter
Gary Cutter University of Alabama at Birmingham
Emmanuelle Waubant
Emmanuelle Waubant University of California, San Francisco
Massimo Filippi
Massimo Filippi Vita-Salute San Raffaele University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re considering a career in medicine but want flexible study options, several online degree pathways may align with your goals. For registered nurses, adn to fnp bridge programs allow you to advance quickly into family nurse practitioner roles without starting from scratch. Current RNs can also enroll in an rn to bsn online without clinicals pathway, ideal for those seeking advancement while balancing work and home life.

Beyond nursing, there is growing demand for preventive care and wellness expertise. Earning a nutrition degrees online qualification can prepare you for roles in community health, dietetics, and wellness coaching. For those interested in healthcare leadership, whats the best online mha program for working adults covers how to lead hospitals and health organizations without interrupting your current career.

These diverse options reflect the evolving landscape of medical education, making it easier to upskill or transition into rewarding roles in healthcare—entirely online.

Best Scientists Citing Douglas S. Goodin

Trending Scientists